CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Chu, Dake ^a,b   Zhu, Shaojun ^c   Li, Jipeng ^a   Ji, Gang ^a   Wang, Weizhong ^a   Wu, Guosheng ^a   Zheng, Jianyong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; TUMOR MARKER; BSG PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION; UPREGULATION; ADENOCARCINOMA; AGED; GENE EXPRESSION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; SURVIVAL;

ADENOCARCINOMA; AGED; ANTIGENS, CD147; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903625412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101027     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. An JY, Kim KM, Kim YM, Cheong JH, Hyung WJ, et al. (2012) Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. Ann Surg Oncol 19: 2452-2458.
4. Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20.
5. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJ (1997) Matrix metalloproteinases. Br J Surg 84: 160-166. (Pubitemid 27073454)
6. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, et al. (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol 166: 209-219. (Pubitemid 40051673)
7. Yu XL, Hu T, Du JM, Ding JP, Yang XM, et al. (2008) Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem 283: 18056-18065.
8. Luo J, Teplyakov A, Obmolova G, Malia T, Wu SJ, et al. (2009) Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping. Proteins 77: 1009-1014.
9. Tang Y, Kesavan P, Nakada MT, Yan L (2004) Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2: 73-80. (Pubitemid 38250423)
10. Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, et al. (2006) Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol 80: 147-159.
11. Nakamura K, Kodama J, Hongo A, Hiramatsu Y (2012) Role of emmprin in endometrial cancer. BMC Cancer 12: 191.
12. Curran S, Murray GI (2000) Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36: 1621-1630. (Pubitemid 30616366)
13. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S (2005) EMMPRIN/ CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87: 361-368. (Pubitemid 40387615)
14. Pan Y, He B, Song G, Bao Q, Tang Z, et al. (2012) CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol Rep 27: 2003-2009.
15. Piao S, Zhao S, Guo F, Xue J, Yao G, et al. (2012) Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol 138: 627-635.
16. Wang B, Xu YF, He BS, Pan YQ, Zhang LR, et al. (2010) RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res 29: 61.
17. Zou W, Yang H, Hou X, Zhang W, Chen B, et al. (2007) Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910 pm cells. Cancer Lett 248: 211-218. (Pubitemid 46330554)
18. Zhong X, Li M, Nie B, Wu F, Zhang L, et al. (2012) Overexpressions of RACK1 and CD147 Associated with Poor Prognosis in Stage T1 Pulmonary Adenocarcinoma. Ann Surg Oncol.
19. Bi XC, Liu JM, He HC, Ye YK, Han ZD, et al. (2012) Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol 14: 190-196.
20. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, et al. (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11: 312.
21. Afonso J, Longatto-Filho A, Baltazar F, Sousa N, Costa FE, et al. (2011) CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol 37: 811-817.
22. Liu F, Cui L, Zhang Y, Chen L, Wang Y, et al. (2010) Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat 124: 677-688.
23. Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, et al. (2006) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95: 1371-1378. (Pubitemid 44760088)
24. Ruiz S, Castro-Castro A, Bustelo XR (2008) CD147 inhibits the nuclear factor of activated T-cells by impairing Vav1 and Rac1 downstream signaling. J Biol Chem 283: 5554-5566.
25. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, et al. (2007) Emmprin and survivin predict response and survival following cisplatincontaining chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-4414. (Pubitemid 47219707)
26. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53: 125-130. (Pubitemid 30075056)
27. Tian L, Zhang Y, Chen Y, Cai M, Dong H, et al. (2013) EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS One 8: e58069.
28. Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, et al. (2009) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 45: 2418-2424.
29. Lescaille G, Menashi S, Cavelier-Balloy B, Khayati F, Quemener C, et al. (2012) EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 12: 115.
30. Xue YJ, Lu Q, Sun ZX (2011) CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol 28: 1363-1372.